Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells
Brigatinib, one of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs), is approved for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC).